Akso Health Group
Akso Health Group (HX) Stock Competitors & Peer Comparison
See (HX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Distribution Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HX | $2.24 | -4.27% | 53.4M | -1.84 | -$1.22 | N/A |
| MCK | $711.82 | +0.23% | 88.9B | 27.68 | $25.71 | +0.40% |
| COR | $290.36 | -0.03% | 56.3B | 33.64 | $8.63 | +0.74% |
| CAH | $157.14 | -0.72% | 37.5B | 24.60 | $6.39 | +1.29% |
| ABC | $179.98 | -0.23% | 36.1B | 21.92 | $8.21 | N/A |
| HSIC | $71.46 | -1.60% | 8.7B | 22.26 | $3.21 | N/A |
| PBH | $76.88 | +0.79% | 3.8B | 17.92 | $4.29 | N/A |
| PDCO | $31.33 | +0.00% | 2.8B | 20.48 | $1.53 | +0.83% |
| GRDN | $20.55 | +1.33% | 1.3B | -12.93 | -$1.59 | N/A |
| OMI | $7.88 | -0.76% | 603.7M | -1.66 | -$4.76 | N/A |
Stock Comparison
HX vs MCK Comparison July 2025
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, MCK has a market cap of 88.9B. Regarding current trading prices, HX is priced at $2.24, while MCK trades at $711.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas MCK's P/E ratio is 27.68. In terms of profitability, HX's ROE is -0.13%, compared to MCK's ROE of -1.33%. Regarding short-term risk, HX is more volatile compared to MCK. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check MCK's competition here
HX vs COR Comparison July 2025
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, COR has a market cap of 56.3B. Regarding current trading prices, HX is priced at $2.24, while COR trades at $290.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas COR's P/E ratio is 33.64. In terms of profitability, HX's ROE is -0.13%, compared to COR's ROE of +2.41%. Regarding short-term risk, HX is more volatile compared to COR. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check COR's competition here
HX vs CAH Comparison July 2025
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, CAH has a market cap of 37.5B. Regarding current trading prices, HX is priced at $2.24, while CAH trades at $157.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas CAH's P/E ratio is 24.60. In terms of profitability, HX's ROE is -0.13%, compared to CAH's ROE of -0.50%. Regarding short-term risk, HX is more volatile compared to CAH. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check CAH's competition here
HX vs ABC Comparison July 2025
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, ABC has a market cap of 36.1B. Regarding current trading prices, HX is priced at $2.24, while ABC trades at $179.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas ABC's P/E ratio is 21.92. In terms of profitability, HX's ROE is -0.13%, compared to ABC's ROE of +2.52%. Regarding short-term risk, HX is more volatile compared to ABC. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check ABC's competition here
HX vs HSIC Comparison July 2025
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, HSIC has a market cap of 8.7B. Regarding current trading prices, HX is priced at $2.24, while HSIC trades at $71.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas HSIC's P/E ratio is 22.26. In terms of profitability, HX's ROE is -0.13%, compared to HSIC's ROE of +0.12%. Regarding short-term risk, HX is more volatile compared to HSIC. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check HSIC's competition here
HX vs PBH Comparison July 2025
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, PBH has a market cap of 3.8B. Regarding current trading prices, HX is priced at $2.24, while PBH trades at $76.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas PBH's P/E ratio is 17.92. In terms of profitability, HX's ROE is -0.13%, compared to PBH's ROE of +0.12%. Regarding short-term risk, HX is more volatile compared to PBH. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check PBH's competition here
HX vs PDCO Comparison July 2025
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, PDCO has a market cap of 2.8B. Regarding current trading prices, HX is priced at $2.24, while PDCO trades at $31.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas PDCO's P/E ratio is 20.48. In terms of profitability, HX's ROE is -0.13%, compared to PDCO's ROE of +0.14%. Regarding short-term risk, HX is more volatile compared to PDCO. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check PDCO's competition here
HX vs GRDN Comparison July 2025
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, GRDN has a market cap of 1.3B. Regarding current trading prices, HX is priced at $2.24, while GRDN trades at $20.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas GRDN's P/E ratio is -12.93. In terms of profitability, HX's ROE is -0.13%, compared to GRDN's ROE of -0.74%. Regarding short-term risk, HX is more volatile compared to GRDN. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check GRDN's competition here
HX vs OMI Comparison July 2025
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, OMI has a market cap of 603.7M. Regarding current trading prices, HX is priced at $2.24, while OMI trades at $7.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas OMI's P/E ratio is -1.66. In terms of profitability, HX's ROE is -0.13%, compared to OMI's ROE of -0.51%. Regarding short-term risk, HX is more volatile compared to OMI. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check OMI's competition here
HX vs ZYXI Comparison July 2025
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, ZYXI has a market cap of 78M. Regarding current trading prices, HX is priced at $2.24, while ZYXI trades at $2.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas ZYXI's P/E ratio is -10.75. In terms of profitability, HX's ROE is -0.13%, compared to ZYXI's ROE of -0.24%. Regarding short-term risk, HX is less volatile compared to ZYXI. This indicates potentially lower risk in terms of short-term price fluctuations for HX.Check ZYXI's competition here
HX vs WGRX Comparison July 2025
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, WGRX has a market cap of 67.5M. Regarding current trading prices, HX is priced at $2.24, while WGRX trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas WGRX's P/E ratio is -1.22. In terms of profitability, HX's ROE is -0.13%, compared to WGRX's ROE of -7.42%. Regarding short-term risk, HX is more volatile compared to WGRX. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check WGRX's competition here
HX vs GEG Comparison July 2025
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, GEG has a market cap of 60.6M. Regarding current trading prices, HX is priced at $2.24, while GEG trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas GEG's P/E ratio is -43.40. In terms of profitability, HX's ROE is -0.13%, compared to GEG's ROE of -0.02%. Regarding short-term risk, HX is more volatile compared to GEG. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check GEG's competition here
HX vs RDGT Comparison July 2025
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, RDGT has a market cap of 7.6M. Regarding current trading prices, HX is priced at $2.24, while RDGT trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas RDGT's P/E ratio is -0.39. In terms of profitability, HX's ROE is -0.13%, compared to RDGT's ROE of -0.20%. Regarding short-term risk, HX is more volatile compared to RDGT. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check RDGT's competition here
HX vs CVET Comparison July 2025
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, CVET has a market cap of 0. Regarding current trading prices, HX is priced at $2.24, while CVET trades at $20.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas CVET's P/E ratio is -69.97. In terms of profitability, HX's ROE is -0.13%, compared to CVET's ROE of -0.06%. Regarding short-term risk, HX is more volatile compared to CVET. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check CVET's competition here